Home » 2017 » November
ViiV Healthcare secures Juluca FDA approval for virologically suppressed HIV-1

ViiV Healthcare secures Juluca FDA approval for virologically suppressed HIV-1

Juluca FDA approval : ViiV Healthcare’s 2-drug regimen Juluca has secured approval from the US Food and Drug Administration (FDA) for the maintenance treatment of virologically suppressed human immunodeficiency virus type 1 (HIV-1) infection. The HIV drug regimen Juluca, which is intended to be taken as a single pill daily once, is a combination of […]

Acalabrutinib wins US FDA approval for mantle cell lymphoma treatment

Acalabrutinib FDA approval : AstraZeneca has secured an early approval for its blood cancer drug Calquence (acalabrutinib) for the treatment of mantle cell lymphoma in adult patients who were subjected to a minimum of one prior therapy for the rare type of blood cancer. According to the National Cancer Institute at the National Institutes of […]

Continue reading …